Skip to main content
SpringerLink
Log in

MiR-495-3p and miR-143-3p co-target CDK1 to inhibit the development of cervical cancer

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

The GEO database and KEGG database-based analyses identified the differential expression of cyclin-dependent kinase 1 (CDK1) in cervical cancer and its involvement in the cell cycle pathway. In the present study, we aim to clarify the role of CDK1 in cervical cancer and the function of upstream microRNA (miR)-143-3p/miR-495-3p.

Methods

The expression of miR-143-3p, miR-495-3p, and CDK1 in cervical cancer tissues and cells was determined using RT-qPCR. Cell bioactivities were examined by CCK-8 and flow cytometry. The binding affinity between CDK1 and miR-143-3p/miR-495-3p was investigated using dual luciferase gene reporter assay. A xenograft mouse model of cervical cancer was then established to explore their effect on the tumorigenicity of cervical cancer cells in vivo.

Results

CDK1 was found to be the common target gene of miR-143-3p and miR-495-3p. CDK1 overexpression occurred in cervical cancer tissues and cells, while expression of miR-495-3p and miR-143-3p was down-regulated. The viability was inhibited while the apoptosis was promoted in cervical cancer cells in response to miR-143-3p or miR-495-3p overexpression, or CDK1 silencing. Further, miR-143-3p or miR-495-3p overexpression was also substantiated to inhibit the tumorigenicity of cervical cancer cells in vivo, while CDK1 overexpression counteracted their effect.

Conclusion

Taken together, miR-143-3p and miR-495-3p co-target CDK1, thereby inhibiting the occurrence and development of cervical cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Dai Y, Xie F, Chen Y. Reduced levels of miR-485-5p in HPV-infected cervical cancer promote cell proliferation and enhance invasion ability. FEBS Open Bio. 2020;10(7):1348–61. https://doi.org/10.1002/2211-5463.12869.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Diouf D, Diop G, Diarra CAT, Ngom AI, Niane K, Ndiaye M, et al. Systematic screening for cervical cancer in Dakar region: prevalence and correlation with biological and socio-demographic parameters. Infect Agent Cancer. 2020. https://doi.org/10.1186/s13027-020-00290-y.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Liu J, Shi Y, Wang L, Wang J, Fan D, Han S, et al. Epidemiology and persistence of cervical human papillomavirus infection among outpatient women in Heilongjiang province: A retrospective cohort study. J Med Virol. 2020. https://doi.org/10.1002/jmv.25899.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Li J, Zhou C, Zhou H, Bao T, Gao T, Jiang X, et al. The association between methylated CDKN2A and cervical carcinogenesis, and its diagnostic value in cervical cancer: a meta-analysis. Ther Clin Risk Manag. 2016. https://doi.org/10.2147/TCRM.S108094.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Yadav N, Parveen S, Banerjee M. Potential of nano-phytochemicals in cervical cancer therapy. Clin Chim Acta. 2020. https://doi.org/10.1016/j.cca.2020.01.035.

    Article  PubMed  Google Scholar 

  6. Ma D, Zhang YY, Guo YL, Li ZJ, Geng L. Profiling of microRNA-mRNA reveals roles of microRNAs in cervical cancer. Chin Med J (Engl). 2012;125(23):4270–6.

    CAS  Google Scholar 

  7. Williams AE, Moschos SA, Perry MM, Barnes PJ, Lindsay MA. Maternally imprinted microRNAs are differentially expressed during mouse and human lung development. Dev Dyn. 2007;236(2):572–80. https://doi.org/10.1002/dvdy.21047.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Eun JW, Kim HS, Shen Q, Yang HD, Kim SY, Yoon JH, et al. MicroRNA-495-3p functions as a tumor suppressor by regulating multiple epigenetic modifiers in gastric carcinogenesis. J Pathol. 2018;244(1):107–19. https://doi.org/10.1002/path.4994.

    Article  CAS  PubMed  Google Scholar 

  9. Zhao G, Zhang L, Qian D, Sun Y, Liu W. miR-495–3p inhibits the cell proliferation, invasion and migration of osteosarcoma by targeting C1q/TNF-related protein 3. Onco Targets Ther. 2019. https://doi.org/10.2147/OTT.S193937.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Gang X, Yuan M, Zhang J. Long Non-Coding RNA TMPO-AS1 Promotes cervical cancer cell proliferation, migration, and invasion by regulating miR-143–3p/ZEB1 axis. Cancer Manag Res. 2020;12:1587–99. https://doi.org/10.2147/CMAR.S226409.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Liu M, Jia J, Wang X, Liu Y, Wang C, Fan R. Long non-coding RNA HOTAIR promotes cervical cancer progression through regulating BCL2 via targeting miR-143-3p. Cancer Biol Ther. 2018;19(5):391–9. https://doi.org/10.1080/15384047.2018.1423921.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Diril MK, Ratnacaram CK, Padmakumar VC, Du T, Wasser M, Coppola V, et al. Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration. Proc Natl Acad Sci USA. 2012;109(10):3826–31. https://doi.org/10.1073/pnas.1115201109.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Deng YR, Chen XJ, Chen W, Wu LF, Jiang HP, Lin D, et al. Sp1 contributes to radioresistance of cervical cancer through targeting G2/M cell cycle checkpoint CDK1. Cancer Manag Res. 2019;11:5835–44. https://doi.org/10.2147/CMAR.S200907.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Li L, Thakur K, Cao YY, Liao BY, Zhang JG, Wei ZJ. Anticancerous potential of polysaccharides sequentially extracted from Polygonatum cyrtonema Hua in human cervical cancer hela cells. Int J Biol Macromol. 2020;148:843–50. https://doi.org/10.1016/j.ijbiomac.2020.01.223.

    Article  CAS  PubMed  Google Scholar 

  15. Huang C, Huang J, Ma P, Yu G. microRNA-143 acts as a suppressor of hemangioma growth by targeting Bcl-2. Gene. 2017;628:211–7. https://doi.org/10.1016/j.gene.2017.07.046.

    Article  CAS  PubMed  Google Scholar 

  16. He Z, Dang J, Song A, Cui X, Ma Z, Zhang Z. NEAT1 promotes colon cancer progression through sponging miR-495-3p and activating CDK6 in vitro and in vivo. J Cell Physiol. 2019;234(11):19582–91. https://doi.org/10.1002/jcp.28557.

    Article  CAS  PubMed  Google Scholar 

  17. Han B, Zhang Y, Zhang Y, Bai Y, Chen X, Huang R, et al. Novel insight into circular RNA HECTD1 in astrocyte activation via autophagy by targeting MIR142-TIPARP: implications for cerebral ischemic stroke. Autophagy. 2018;14(7):1164–84. https://doi.org/10.1080/15548627.2018.1458173.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Luo Y, Wu Y, Peng Y, Liu X, Bie J, Li S. Systematic analysis to identify a key role of CDK1 in mediating gene interaction networks in cervical cancer development. Ir J Med Sci. 2016;185(1):231–9. https://doi.org/10.1007/s11845-015-1283-8.

    Article  CAS  PubMed  Google Scholar 

  19. Chen YF, Cho JJ, Huang TH, Tseng CN, Huang EY, Cho CL. Downregulation of a novel human gene, ROGDI, increases radiosensitivity in cervical cancer cells. Cancer Biol Ther. 2016;17(10):1070–8. https://doi.org/10.1080/15384047.2016.1219818.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Song L, Wang L, Pan X, Yang C. lncRNA OIP5-AS1 targets ROCK1 to promote cell proliferation and inhibit cell apoptosis through a mechanism involving miR-143-3p in cervical cancer. Braz J Med Biol Res. 2020;53(1):e8883. https://doi.org/10.1590/1414-431X20198883.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Yang J, Jiang B, Hai J, Duan S, Dong X, Chen C. Long noncoding RNA opa-interacting protein 5 antisense transcript 1 promotes proliferation and invasion through elevating integrin alpha6 expression by sponging miR-143-3p in cervical cancer. J Cell Biochem. 2019;120(1):907–16. https://doi.org/10.1002/jcb.27454.

    Article  CAS  PubMed  Google Scholar 

  22. Cui N, Liu J, Xia H, Xu D. LncRNA SNHG20 contributes to cell proliferation and invasion by upregulating ZFX expression sponging miR-495-3p in gastric cancer. J Cell Biochem. 2019;120(3):3114–23. https://doi.org/10.1002/jcb.27539.

    Article  CAS  PubMed  Google Scholar 

  23. Chen SM, Chen HC, Chen SJ, Huang CY, Chen PY, Wu TW, et al. MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6. World J Surg Oncol. 2013;11:87. https://doi.org/10.1186/1477-7819-11-87.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Cheng W, Yan K, Xie LY, Chen F, Yu HC, Huang YX, et al. MiR-143–3p controls TGF-beta1-induced cell proliferation and extracellular matrix production in airway smooth muscle via negative regulation of the nuclear factor of activated T cells 1. Mol Immunol. 2016;78:133–9. https://doi.org/10.1016/j.molimm.2016.09.004.

    Article  CAS  PubMed  Google Scholar 

  25. Zhu H DU, Mustafi R, et al. 679 Putative Tumor Suppressors miR-143 and miR-145 Inhibit HCT116 Colon Cancer Cell Growth in Tumor Xenografts, Roles of K-RAS, MYC, Ccnd2 and Cdk6. Gastroenterology. 2010;138(5-supp-S1):S–93.

Download references

Acknowledgements

We would like to give our sincere appreciation to the reviewers for their helpful comments on this article.

Funding

None.

Author information

Author notes

  1. Jie Tang, Hongchao Pan and Weiwei Wang are regarded as co-first authors.

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou Normal University, Huzhou, 313003, People’s Republic of China

    J. Tang

  2. Department of Laboratory Medicine, Shanghai Simple Gene Medical Laboratory, Shanghai, 200025, People’s Republic of China

    H. Pan

  3. Department of Pathology, The Sixth People’s Hospital of Yancheng City, Yancheng, 224005, People’s Republic of China

    W. Wang, C. Qi & A. Shang

  4. Department of Laboratory Medicine, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, 200065, People’s Republic of China

    C. Gu & A. Shang

  5. Department of Laboratory Medicine, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou Normal University, Huzhou, 313003, Zhejiang Province, People’s Republic of China

    J. Zhu

Authors
  1. J. Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Shang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Jie Tang, Hongchao Pan and Weiwei Wang designed the study. Chunrun Qi and Chenzheng Gu collated the data, carried out data analyses and produced the initial draft of the manuscript. Jie Tang, Hongchao Pan, Anquan Shang and Jichao Zhu contributed to drafting the manuscript. All authors have read and approved the final submitted manuscript.

Corresponding authors

Correspondence to A. Shang or J. Zhu.

Ethics declarations

Conflict of interest

The authors have reported that no potential conflicts of interest exist.

Ethical approval

This study, under approval of Ethics Committee of Huzhou Central Hospital, was conducted with informed consent provided by all participants, strictly following the Declaration of Helsinki. The animal experiments was approved by the Animal Ethics Committee of Huzhou Central Hospital.

Informed consent This study was conducted with informed consent from all participants.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 14 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, J., Pan, H., Wang, W. et al. MiR-495-3p and miR-143-3p co-target CDK1 to inhibit the development of cervical cancer. Clin Transl Oncol 23, 2323–2334 (2021). https://doi.org/10.1007/s12094-021-02687-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-021-02687-6

Keywords

Search

Navigation